UK MHRA assesses cost to industry of complying with new EU law on falsified medicines
This article was originally published in SRA
Executive Summary
The UK Medicines and Healthcare products Agency has taken the first steps towards preparing an economic impact assessment of the anticipated costs to the pharmaceutical industry in meeting the regulatory obligations of the the EU's falsified medicines directive1.